Publications by authors named "Elizabeth Alli"

Claim this Profile
R
Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
Adrian J Rodrigues, Sophia B Chernikova, Yuelong Wang, Thy T H Trinh, David E Solow-Cordero, Elizabeth Alli

J Neurooncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease.
Adrian Rodrigues, Sophia B Chernikova, Yuelong Wang, Thy T H Trinh, David E Solow-Cordero, Elizabeth Alli

Res Sq· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silver nanoparticles selectively treat triple-negative breast cancer cells without affecting non-malignant breast epithelial cells in vitro and in vivo.
Jessica Swanner, Cale D Fahrenholtz, Iliana Tenvooren, Brian W Bernish, James J Sears, Allison Hooker, Elizabeth Alli

FASEB Bioadv· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correcting errors in the BRCA1 warning system.
Yanping Liang, William J Dearnaley, Nick A Alden, Maria J Solares, Brian L Gilmore, Elizabeth Alli

DNA Repair (Amst)· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1: a movement toward cancer prevention.
Elizabeth Alli, James M Ford

Mol Cell Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1: Beyond double-strand break repair.
Elizabeth Alli, James M Ford

DNA Repair (Amst)· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Elizabeth Alli, David Solow-Cordero, Stephanie C Casey, James M Ford

Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Shaveta Vinayak, Erich J Schwartz, Kristin Jensen, Jafi Lipson, Elizabeth Alli, Allison W Kurian

Breast Cancer Res Treat· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
Elizabeth Alli, James M Ford

DNA Repair (Amst)· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Elizabeth Alli, Vandana B Sharma, Anne-Renee Hartman, Patrick S Lin, Lisa McPherson

BMC Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Kedar Hastak, Elizabeth Alli, James M Ford

Cancer Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Elizabeth Alli, Vandana B Sharma, Preethi Sunderesakumar, James M Ford

Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Elizabeth Alli, Jin-Ming Yang, James M Ford, William N Hait

Mol Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Elizabeth Alli, Judy Bash-Babula, Jin-Ming Yang, William N Hait

Cancer Res· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.
Judy Bash-Babula, Deborah Toppmeyer, Marie Labassi, Janice Reidy, Michelle Orlick, Elizabeth Alli

Clin Cancer Res· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis